证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-044 浙江莎普爱思药业股份有限公司 第六届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江莎普爱思药业股份有限公司（以下简称"公司"）第六届监事会第九次会议于 2025年8月29日以通讯方式召开。本次监事会已于2025年8月19日以电子邮件、电话、微 信等方式通知全体监事。本次会议由许晓森先生主持，会议应出席监事3人，实际出席 监事3人。本次会议的召开符合《公司法》和《公司章程》等有关规定，会议决议合法、 有效。 二、监事会会议审议情况 经全体监事逐项审议，通过了如下议案： 1、审议通过《关于2025年半年度报告及摘要的议案》。 监事会认为：公司2025年半年度报告全文及摘要所披露的信息真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带责任。 一、监事会会议召开情况 3、审议通过《关于取消监事会并废止<监事会议事规则>的议案》。 根据《中华人民共和国公司法》《关于新<公司 ...

证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-043 浙江莎普爱思药业股份有限公司 第六届董事会第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江莎普爱思药业股份有限公司(以下简称"公司")第六届董事会第九次会议于 2025年8月29日以现场及通讯方式召开，其中董事汪为民先生、董事吴建国先生、独立 董事颜世富先生、孙继伟先生以通讯方式表决。本次董事会已于2025年8月19日以电子 邮件、电话、微信等方式通知全体董事、监事、高级管理人员。会议应出席董事9人， 实际出席董事9人。公司监事许晓森先生、陆霞女士、全莉女士列席了本次会议；副总 经理徐洪胜先生列席了本次会议（均以视频方式列席），均知悉本次会议相关情况。本 次会议的召开符合《公司法》和《公司章程》等有关规定，会议决议合法、有效。 二、董事会会议审议情况 经全体董事逐项审议，通过了如下议案： 1、审议通过《关于2025年半年度报告及摘要的议案》。 同意并对外披露《浙江莎普爱思药业股份有限公司2025年半年度报 ...

[Important Notes](index=2&type=section&id=%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) The Board of Directors, Supervisory Committee, and senior management guarantee the authenticity, accuracy, and completeness of this semi-annual report[5](index=5&type=chunk) - The Board of Directors, Supervisory Committee, and senior management of the company guarantee the truthfulness, accuracy, and completeness of the semi-annual report's content, bear individual and joint legal responsibility, and affirm there are no false records, misleading statements, or major omissions[5](index=5&type=chunk) - This semi-annual report is **unaudited**[7](index=7&type=chunk) - The company's responsible person Lin Hongli, chief financial officer Lin Xiusong, and head of the accounting department Lin Xiusong declare that the financial report herein is truthful, accurate, and complete[7](index=7&type=chunk) - No profit distribution or conversion of capital reserve to share capital is proposed for this reporting period[8](index=8&type=chunk) - Forward-looking statements in this report regarding future plans and development strategies do not constitute a commitment to investors, who are advised to be aware of investment risks[8](index=8&type=chunk) - There are no instances of non-operating fund occupation by the controlling shareholder or other related parties, nor any provision of external guarantees in violation of decision-making procedures[9](index=9&type=chunk) - The company has detailed existing risks in this report, please refer to "Section 3 Management Discussion and Analysis, V. Other Disclosures, (I) Potential Risks"[9](index=9&type=chunk) [Section 1 Definitions](index=4&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8A%E4%B9%89) This section defines frequently used terms to ensure a clear understanding of the report's content[15](index=15&type=chunk) - "Company," "the Company," or "Shapuaisi" refers to Zhejiang Shapuaisi Pharmaceutical Co, Ltd[15](index=15&type=chunk) - "Reporting Period" or "Current Period" refers to the period from January 1, 2025, to June 30, 2025[15](index=15&type=chunk) - "Shapuaisi Eye Drops" refers to the Bendazac Lysine Eye Drops (trade name: Shapuaisi) produced by the company[15](index=15&type=chunk) [Section 2 Company Profile and Key Financial Indicators](index=5&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section provides the company's basic information and key financial data, highlighting a turnaround to profitability in the first half of 2025 - The company's Chinese name is 浙江莎普爱思药业股份有限公司, the abbreviation is 莎普爱思, and the legal representative is Lin Hongli[17](index=17&type=chunk) - The company's stock is listed on the Shanghai Stock Exchange with the stock name "Shapuaisi" and stock code "603168"[21](index=21&type=chunk) - The company's designated information disclosure newspapers are China Securities Journal, Shanghai Securities News, Securities Times, and Securities Daily, with the semi-annual report available at www.sse.com.cn[20](index=20&type=chunk) Key Accounting Data for H1 2025 | Indicator | Current Period (Jan-Jun) | Prior Year Period | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 236,090,840.96 | 236,852,225.90 | -0.32 | | Total Profit | 21,428,042.32 | -20,663,325.25 | N/A (Turnaround to Profitability) | | Net Profit Attributable to Shareholders | 21,862,855.49 | -24,716,934.81 | N/A (Turnaround to Profitability) | | Net Cash Flow from Operating Activities | 51,450,766.00 | -10,125,489.07 | N/A (Significant Growth) | | Net Assets Attributable to Shareholders (End of Period) | 1,613,043,799.81 | 1,589,629,316.96 | 1.47 | | Total Assets (End of Period) | 2,103,716,207.09 | 2,106,253,035.91 | -0.12 | Key Financial Indicators for H1 2025 | Indicator | Current Period (Jan-Jun) | Prior Year Period | Change (%) | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share (yuan/share) | 0.06 | -0.07 | N/A (Turnaround to Profitability) | | Diluted Earnings Per Share (yuan/share) | 0.06 | -0.07 | N/A (Turnaround to Profitability) | | Weighted Average Return on Equity (%) | 1.37 | -1.45 | Increased by 2.81 percentage points | | Weighted Average ROE after Non-recurring Items (%) | 1.35 | -1.47 | Increased by 2.82 percentage points | - During the reporting period, the company achieved **operating revenue of 236.09 million yuan**, a slight decrease of 0.32% year-on-year, while **net profit attributable to shareholders was 21.86 million yuan**, marking a turnaround to profitability due to cost reduction and efficiency improvement measures[24](index=24&type=chunk) Non-recurring Gains and Losses for H1 2025 | Non-recurring Item | Amount (yuan) | | :--- | :--- | | Gains/losses from disposal of non-current assets, including write-offs of asset impairment provisions | 788,664.70 | | Government grants recognized in current profit or loss, excluding those closely related to normal business operations | 4,828,915.45 | | Fair value changes and disposal gains/losses from financial assets and liabilities held by non-financial enterprises, excluding effective hedging activities | -5,966,552.53 | | Other non-operating income and expenses | 277,911.25 | | Less: Income tax impact | 249,632.71 | | Total | 178,571.58 | [Section 3 Management Discussion and Analysis](index=8&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E7%AE%A1%E7%90%86%E5%B1%82%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) The company's "pharmaceutical + medical" dual-driver strategy led to a turnaround to profitability despite facing multiple industry risks and policy changes - The company focuses on a "pharmaceutical + medical" dual-driver strategy, engaging in drug R&D, production, sales, and medical services[30](index=30&type=chunk) - In the reporting period, the company achieved **operating revenue of 236.09 million yuan** and **net profit attributable to shareholders of 21.86 million yuan**, achieving a turnaround to profitability[36](index=36&type=chunk) - The company faces risks from medical management, industry policy changes, rising R&D costs, environmental safety, medical incidents, and declining birth rates[57](index=57&type=chunk)[58](index=58&type=chunk) - The consistency evaluation of Bendazac Lysine Eye Drops (Shapuaisi) is still in progress, with a risk of not passing regulatory approval even after completion[58](index=58&type=chunk) [I. Industry and Core Business Overview](index=8&type=section&id=%E4%B8%80%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E6%89%80%E5%B1%9E%E8%A1%8C%E4%B8%9A%E5%8F%8A%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E6%83%85%E5%86%B5%E8%AF%B4%E6%98%8E) The company operates in the pharmaceutical manufacturing and medical services sectors, driven by an aging population and supportive government policies - The pharmaceutical manufacturing industry is a strategic sector poised for continued growth, driven by an aging population, rising demand for chronic disease management, and increased public health awareness[30](index=30&type=chunk) - The National Medical Products Administration (NMPA) has issued policies to improve review efficiency, protect innovative drug data, and strengthen full-chain management[30](index=30&type=chunk)[31](index=31&type=chunk) - The medical services industry is supported by policies encouraging social capital investment to meet diverse healthcare needs amid an aging population[32](index=32&type=chunk) - The company's pharmaceutical manufacturing segment focuses on ophthalmic drugs (anti-cataract), anti-microbial drugs (cephalosporins, quinolones), with key products including Bendazac Lysine Eye Drops and Cefixime products[34](index=34&type=chunk) - The medical services segment includes Taizhou Maternity Hospital (a Grade II Class A specialty hospital) and Qingdao Shijian Eye Hospital (specializing in ophthalmic medical services)[34](index=34&type=chunk) - The pharmaceutical manufacturing segment utilizes a unified procurement and GMP-compliant production model, with sales through distributors and direct supply to hospitals[34](index=34&type=chunk)[35](index=35&type=chunk) - The medical services segment builds its market reputation through enhanced internal management, high-quality medical services, brand building, and community engagement[35](index=35&type=chunk) [II. Discussion and Analysis of Operations](index=9&type=section&id=%E4%BA%8C%E3%80%81%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5%E7%9A%84%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) The company achieved a turnaround to profitability with revenue of 236 million yuan, driven by its dual-driver strategy and cost control measures - During the reporting period, the company achieved **operating revenue of 236.09 million yuan** and **net profit attributable to shareholders of 21.86 million yuan**[36](index=36&type=chunk) - In H1 2025, **R&D investment was 22.92 million yuan**, a year-on-year decrease of 56.83%, accounting for 9.71% of operating revenue[37](index=37&type=chunk) Progress of Key R&D Products | Category | Product Name | R&D Progress | | :--- | :--- | :--- | | Eye Drops | Bromfenac Sodium Eye Drops (2 specs), Polyvinyl Alcohol Eye Drops, Tafluprost Eye Drops, Olopatadine Hydrochloride Eye Drops | Obtained drug registration certificates from NMPA | | Capsules, Eye Drops | Cefdinir Capsules, Levofloxacin Eye Drops | Obtained supplementary application approval notices from NMPA | | Dry Suspension, Eye Drops, etc | Azithromycin Dry Suspension, Dapoxetine Hydrochloride Tablets, Compound Tropicamide Eye Drops, Pranoprofen Eye Drops | Applications submitted to NMPA and under CDE review | | Eye Drops | Atropine Sulfate Eye Drops, Pilocarpine Hydrochloride Eye Drops | In research and development stage | - The company continues to advance the consistency evaluation of Bendazac Lysine Eye Drops (Shapuaisi)[38](index=38&type=chunk) - In H1 2025, the company's drug quality management system operated effectively, ensuring product compliance with no major quality incidents[38](index=38&type=chunk) - The company adhered to its "safety first, prevention foremost, comprehensive management" policy, with no major production safety accidents during the period[39](index=39&type=chunk) - The company maintained deep connections with the capital market through transparent communication, including earnings calls and institutional investor meetings[39](index=39&type=chunk) - The company actively fulfilled its social responsibilities through cultural events, eye health education, and community outreach by its subsidiary hospitals[40](index=40&type=chunk)[41](index=41&type=chunk) [III. Analysis of Core Competencies](index=11&type=section&id=%E4%B8%89%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) The company's core strengths lie in its established brand recognition, extensive sales network, and specialized medical services enhanced by expert collaborations - **Pharmaceutical Manufacturing**: The core product, Bendazac Lysine Eye Drops, holds a leading position in the cataract drug market with strong brand recognition[42](index=42&type=chunk) - **Pharmaceutical Manufacturing**: The company has established a nationwide marketing network and an OTC product team employing a "full-channel management" model[42](index=42&type=chunk) - **Pharmaceutical Manufacturing**: The company emphasizes new product development through a combination of in-house R&D and industry-academia-research collaborations, accumulating a solid technology reserve[42](index=42&type=chunk) - **Medical Services**: Taizhou Maternity Hospital enhances its obstetric diagnosis and treatment levels by participating in the Shanghai East Hospital Obstetrics Alliance[43](index=43&type=chunk) - **Medical Services**: Qingdao Shijian Hospital has expanded its services by adding a retinal disease specialty and performing vitrectomy surgeries, enhancing its overall image[43](index=43&type=chunk) [IV. Key Operating Activities](index=11&type=section&id=%E5%9B%9B%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E4%B8%BB%E8%A6%81%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5) The company achieved a turnaround to profitability in H1 2025, driven by significant reductions in operating, administrative, and R&D expenses Key Financial Statement Item Changes in H1 2025 | Item | Current Period (yuan) | Prior Year Period (yuan) | Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 236,090,840.96 | 236,852,225.90 | -0.32 | Slight decrease | | Operating Costs | 93,719,912.44 | 114,977,567.09 | -18.49 | Enhanced cost control and product mix changes | | Selling Expenses | 42,749,181.36 | 42,587,848.47 | 0.38 | - | | Administrative Expenses | 52,512,672.11 | 60,248,963.15 | -12.84 | Enhanced expense control, reduced personnel and office expenses | | Finance Expenses | 4,828,164.24 | 2,695,832.15 | 79.10 | Increased interest expenses | | R&D Expenses | 11,769,078.12 | 35,577,764.98 | -66.92 | Reduced investment in R&D projects | | Net Cash Flow from Operating Activities | 51,450,766.00 | -10,125,489.07 | N/A | Increased profit due to lower expenses | | Net Cash Flow from Investing Activities | -51,035,320.55 | -257,348,885.56 | N/A | Prior year included payment for equity investment and hospital construction | | Net Cash Flow from Financing Activities | 5,436,692.07 | 62,974,670.10 | -91.37 | Decrease in new bank borrowings during the period | Asset and Liability Changes in H1 2025 | Item | End of Current Period (yuan) | End of Prior Period (yuan) | Change (%) | Explanation | | :--- | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 88,639,588.45 | 82,787,450.93 | 7.07 | - | | Trading Financial Assets | 100,417,450.84 | 106,860,727.24 | -6.03 | - | | Accounts Receivable | 33,090,822.39 | 37,868,555.55 | -12.62 | - | | Receivables Financing | 21,661,473.37 | 29,917,053.17 | -27.59 | Increase in note discounting | | Prepayments | 20,250,600.68 | 15,680,054.17 | 29.15 | Increase in prepayments for materials and outsourced R&D | | Inventories | 110,933,958.38 | 76,660,507.89 | 44.71 | Increase in work-in-progress | | Right-of-use Assets | 20,030,293.40 | 29,515,580.77 | -32.14 | Reduction in leased office space | | Development Expenditures | 76,567,631.37 | 65,419,609.56 | 17.04 | - | | Short-term Borrowings | 120,178,802.78 | 105,294,386.11 | 14.14 | - | | Other Payables | 42,515,573.05 | 74,543,074.32 | -42.97 | Payment of equity investment payables and accrued expenses | | Long-term Borrowings | 129,872,835.22 | 111,546,568.98 | 16.43 | - | | Lease Liabilities | 16,968,296.59 | 25,343,822.52 | -33.05 | Reduction in leased office space | Major Restricted Assets as of H1 2025 | Item | Closing Book Balance (yuan) | Closing Book Value (yuan) | Restriction Type | Reason for Restriction | | :--- | :--- | :--- | :--- | :--- | | Fixed Assets | 41,352,744.17 | 25,500,841.27 | Mortgage | Collateral for long-term borrowings | | Total | 41,352,744.17 | 25,500,841.27 | / | / | Financial Assets Measured at Fair Value in H1 2025 | Asset Class | Opening Balance (yuan) | Fair Value Change (yuan) | Purchases (yuan) | Sales/Redemptions (yuan) | Other Changes (yuan) | Closing Balance (yuan) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Stocks | 102,891,597.99 | -8,685,611.12 | 1,663,027,943.31 | 1,663,036,667.18 | 2,719,076.13 | 96,916,339.13 | | Bank Wealth Management Products | 3,501,111.71 | - | - | - | - | 3,501,111.71 | | Other | 20,400,000.00 | - | - | 1,400,000.00 | - | 19,000,000.00 | | Performance Commitment Compensation | 468,017.54 | -17.54 | - | - | -468,000.00 | - | | Total | 127,260,727.24 | -8,685,628.66 | 1,663,027,943.31 | 1,664,436,667.18 | 2,251,076.13 | 119,417,450.84 | - The company sold its 100% stake in the wholly-owned subsidiary Zhejiang Shapuaisi Pharmacy Chain Co, Ltd for **500,000 yuan**, with no significant impact on overall operations or performance[54](index=54&type=chunk)[56](index=56&type=chunk) Performance of Major Subsidiaries and Associates (Unit: ten thousand yuan) | Company Name | Type | Main Business | Registered Capital | Total Assets | Net Assets | Operating Revenue | Operating Profit | Net Profit | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Shapuaisi Sales Co | Subsidiary | Pharmaceutical Commerce | 8,800 | 10,143.19 | 430.41 | 2,396.29 | -3,673.48 | -3,675.58 | | Taizhou Hospital | Subsidiary | Medical Services | 8,695.65 | 62,307.04 | 49,818.78 | 6,145.84 | 462.84 | 406.04 | | Shapu Health | Subsidiary | Software & IT Services | 2,000 | 7,282.04 | 1,903.95 | 0 | -59.09 | -59.07 | | Qingdao Shijian | Subsidiary | Medical Services | 1,000 | 3,305.52 | 2,403.85 | 600.26 | 155.98 | 152.12 | | Jiusongtang Yuan | Subsidiary | Investment | 7,000 | 306.36 | 22.17 | 0 | -2.84 | -2.84 | | Trading Co | Subsidiary | Trading | 10 | 109.65 | 107.75 | 17.04 | 1.73 | 1.64 | | Shanghai Xiongqi Biotech | Subsidiary | Technical Services | 1,000 | 7.51 | -300.66 | 0 | -44.63 | -44.59 | | Pinghu Shapuaisi Limin Pharmacy | Subsidiary | Pharmaceutical Retail | 110 | 205.66 | 88.43 | 55.80 | -21.57 | -21.57 | | Shanghai Xinhong Pharmaceutical | Associate | R&D | 46,000 | 42,849.40 | 42,838.50 | 0 | -1,356.20 | -1,356.20 | [V. Other Disclosures](index=17&type=section&id=%E4%BA%94%E3%80%81%E5%85%B6%E4%BB%96%E6%8A%AB%E9%9C%B2%E4%BA%8B%E9%A1%B9) The company faces significant risks from policy changes, rising costs, and potential failure to pass the consistency evaluation for its core product - The company is exposed to risks from changes in medical and industry management policies, including drug approval, quality supervision, drug bidding, public hospital reform, and medical insurance cost control[57](index=57&type=chunk) - The company faces rising R&D costs due to business expansion, increased operational scale, and the need for continuous investment in cutting-edge technology[57](index=57&type=chunk) - The company is subject to heightened environmental and safety risks due to stricter national regulations on energy conservation, emission reduction, and safety in the pharmaceutical industry[57](index=57&type=chunk) - Despite strict adherence to clinical guidelines, the risk of medical incidents is unavoidable, and the company will continue to enhance safety measures to mitigate this risk[57](index=57&type=chunk) - Taizhou Maternity Hospital faces the risk of a declining birth rate, which could impact its obstetrics department due to a smaller patient base and intense market competition[58](index=58&type=chunk) - There is a risk that the consistency evaluation for Bendazac Lysine Eye Drops (Shapuaisi) may not pass NMPA approval, which would adversely affect the company's operating performance[58](index=58&type=chunk) [Section 4 Corporate Governance, Environment, and Society](index=19&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86%E3%80%81%E7%8E%AF%E5%A2%83%E5%92%8C%E7%A4%BE%E4%BC%9A) This section covers corporate governance updates, environmental disclosures, and social responsibility initiatives undertaken during the reporting period - No changes in directors, supervisors, or senior management occurred during the reporting period[61](index=61&type=chunk) - The semi-annual profit distribution and conversion of capital reserve to share capital proposals are "No," meaning no distribution or conversion will occur[61](index=61&type=chunk) - On April 30, 2025, the company announced the repurchase and cancellation of **1,798,500 restricted shares**, which will reduce the total share capital[62](index=62&type=chunk) - The company is included in the list of enterprises required to disclose environmental information and has provided an index for its 2025 key environmental monitoring unit list[63](index=63&type=chunk)[64](index=64&type=chunk) - The subsidiary Taizhou Maternity Hospital continued its community support by visiting impoverished residents and conducting charitable activities in January and June 2025[64](index=64&type=chunk) [Section 5 Significant Matters](index=21&type=section&id=%E7%AC%AC%E4%BA%94%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) This section details the strict fulfillment of commitments, the absence of major litigation, and the progress of fundraising projects and other key corporate actions - All commitments made by the company's actual controllers, shareholders, related parties, and the company itself were strictly fulfilled during the reporting period[66](index=66&type=chunk) - The company had **no major litigation or arbitration matters** during the reporting period[74](index=74&type=chunk) - The company had no major related-party transactions related to daily operations, asset acquisitions, equity transactions, joint investments, or related-party debts[76](index=76&type=chunk)[77](index=77&type=chunk) Overall Use of Raised Funds | Funding Source | Total Raised (yuan) | Net Proceeds (yuan) | Pledged Investment (yuan) | Cumulative Investment (yuan) | Investment Progress (%) | Current Year Investment (yuan) | Current Year Investment as % of Total | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Private Placement | 317,999,993.22 | 308,243,745.55 | 308,243,745.55 | 309,129,408.19 | 100.29 | 5,681,647.66 | 1.84 | | Total | 317,999,993.22 | 308,243,745.55 | 308,243,745.55 | 309,129,408.19 | / | 5,681,647.66 | / | - The company continues to advance the consistency evaluation of Bendazac Lysine Eye Drops (Shapuaisi), having completed and submitted the post-marketing clinical study to the NMPA[83](index=83&type=chunk) [I. Fulfillment of Commitments](index=21&type=section&id=%E4%B8%80%E3%80%81%E6%89%BF%E8%AF%BA%E4%BA%8B%E9%A1%B9%E5%B1%A5%E8%A1%8C%E6%83%85%E5%86%B5) All commitments made by the company, its controlling shareholders, and management regarding disclosure, competition, and shareholding were strictly fulfilled - The company commits to compensating investors for losses if the prospectus contains false records, misleading statements, or major omissions[66](index=66&type=chunk) - The controlling shareholder and its concerted parties have committed to resolving non-competition issues by refraining from developing or operating businesses that compete with the company[66](index=66&type=chunk)[67](index=67&type=chunk)[68](index=68&type=chunk) - Directors, supervisors, and senior management have committed to limiting annual share transfers to **no more than 25% of their holdings** while in office and not transferring any shares within six months of departure[67](index=67&type=chunk) - The controlling shareholder Shanghai Yanghe Industrial Co, Ltd, and Lin Hongyuan have committed not to reduce their direct or indirect holdings for **36 months** following the completion of the private placement[69](index=69&type=chunk)[70](index=70&type=chunk) - The company commits not to provide loans or any other form of financial assistance to any incentive plan participants for acquiring relevant interests[70](index=70&type=chunk) - The actual controllers commit to minimizing related-party transactions between their controlled entities and Shapuaisi and its subsidiaries[71](index=71&type=chunk)[72](index=72&type=chunk) - The actual controllers commit to maintaining the company's independence in personnel, assets, finance, organization, and business operations[73](index=73&type=chunk) [VII. Major Litigation and Arbitration](index=28&type=section&id=%E4%B8%83%E3%80%81%E9%87%8D%E5%A4%A7%E8%AF%89%E8%AE%BC%E3%80%81%E4%BB%B2%E8%A3%81%E4%BA%8B%E9%A1%B9) The company had no major litigation or arbitration matters during the reporting period[74](index=74&type=chunk) - The company had **no major litigation or arbitration matters** during this reporting period[74](index=74&type=chunk) [X. Major Related-Party Transactions](index=29&type=section&id=%E5%8D%81%E3%80%81%E9%87%8D%E5%A4%A7%E5%85%B3%E8%81%94%E4%BA%A4%E6%98%93) No major related-party transactions occurred during the reporting period in relation to daily operations, asset acquisitions, or financing activities - The company had **no related-party transactions** related to daily operations during the reporting period[76](index=76&type=chunk) - The company had **no related-party transactions** involving the acquisition or sale of assets or equity during the reporting period[76](index=76&type=chunk) - The company had **no major related-party transactions** involving joint external investments during the reporting period[76](index=76&type=chunk) - The company had **no related-party credit or debt transactions** during the reporting period[76](index=76&type=chunk)[77](index=77&type=chunk) [XII. Progress on the Use of Raised Funds](index=31&type=section&id=%E5%8D%81%E4%BA%8C%E3%80%81%E5%8B%9F%E9%9B%86%E8%B5%84%E9%87%91%E4%BD%BF%E7%94%A8%E8%BF%9B%E5%B1%95%E8%AF%B4%E6%98%8E) The company has fully utilized the 308 million yuan in net proceeds, with investment progress reaching 100.29% as of the report date Overall Use of Raised Funds | Funding Source | Total Raised (yuan) | Net Proceeds (yuan) | Pledged Investment (yuan) | Cumulative Investment (yuan) | Investment Progress (%) | Current Year Investment (yuan) | Current Year Investment as % of Total | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Private Placement | 317,999,993.22 | 308,243,745.55 | 308,243,745.55 | 309,129,408.19 | 100.29 | 5,681,647.66 | 1.84 | | Total | 317,999,993.22 | 308,243,745.55 | 308,243,745.55 | 309,129,408.19 | / | 5,681,647.66 | / | Detailed Use of Raised Funds (Unit: yuan) | Project Name | Pledged Investment | Current Year Investment | Cumulative Investment | Investment Progress (%) | Expected Completion Date | | :--- | :--- | :--- | :--- | :--- | :--- | | Taizhou Women's and Children's Hospital New Building Project | 231,182,845.55 | 5,679,500.00 | 232,066,360.53 | 100.38 | September 30, 2025 | | Supplementary Working Capital | 77,060,900.00 | 2,147.66 | 77,063,047.66 | 100.00 | N/A | | Total | 308,243,745.55 | 5,681,647.66 | 309,129,408.19 | / | / | - The company had no changes to or termination of investment projects using raised funds during the reporting period[82](index=82&type=chunk) [XIII. Explanation of Other Significant Matters](index=33&type=section&id=%E5%8D%81%E4%B8%89%E3%80%81%E5%85%B6%E4%BB%96%E9%87%8D%E5%A4%A7%E4%BA%8B%E9%A1%B9%E7%9A%84%E8%AF%B4%E6%98%8E) The company continues to advance the consistency evaluation for its core product, Bendazac Lysine Eye Drops, having completed the post-marketing clinical study - The company continues to fully advance the consistency evaluation work for Bendazac Lysine Eye Drops (Shapuaisi)[83](index=83&type=chunk) - The post-marketing clinical study for Bendazac Lysine Eye Drops (Shapuaisi) has been completed and submitted to the NMPA as required[83](index=83&type=chunk) [Section 6 Changes in Share Capital and Shareholders](index=35&type=section&id=%E7%AC%AC%E5%85%AD%E8%8A%82%20%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E5%8F%8A%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) This section details the company's stable share structure, shareholder count, and the holdings of its top ten shareholders as of the period end - The company's total share count and capital structure remained unchanged during the reporting period[85](index=85&type=chunk) - As of the end of the reporting period, the total number of common shareholders was **27,615**[86](index=86&type=chunk) Top Ten Shareholders as of Period End | Shareholder Name | Change in Period (shares) | Shares Held at Period End | Percentage (%) | Restricted Shares Held | Share Status | Quantity (shares) | Shareholder Type | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Shanghai Yanghe Industrial Co, Ltd | 0 | 78,249,836 | 20.82 | 47,095,761 | Pledged | 33,850,000 | Domestic Non-state-owned Legal Entity | | Chen Dekang | -2,752,200 | 44,231,004 | 11.77 | 0 | None | 0 | Domestic Individual | | Lin Hongyuan | 0 | 28,953,386 | 7.70 | 2,825,745 | Pledged | 11,013,700 | Domestic Individual | | Shanghai Jingxing Industrial Investment Co, Ltd | -3,167,700 | 12,982,726 | 3.45 | 0 | None | 0 | Domestic Non-state-owned Legal Entity | | Shanghai Tonghui Medical Management Co, Ltd | 0 | 8,762,083 | 2.33 | 0 | Pledged | 8,762,083 | Domestic Non-state-owned Legal Entity | | Hu Zhengguo | 0 | 6,520,000 | 1.73 | 60,000 | None | 0 | Domestic Individual | | Shanghai Yihe Medical Management Co, Ltd | 0 | 6,000,000 | 1.60 | 0 | None | 0 | Domestic Non-state-owned Legal Entity | | Dai Dongjian | 0 | 2,337,370 | 0.62 | 0 | None | 0 | Unknown | | Shanghai Chengzhou Investment - Chengzhou Jinze Yesheng Private Fund | 0 | 2,237,800 | 0.60 | 0 | None | 0 | Unknown | | Zhang Yonggang | 700,000 | 1,750,000 | 0.47 | 0 | None | 0 | Unknown | - Shareholders Yihe Medical and Tonghui Medical are wholly-owned subsidiaries of the controlling shareholder Yanghe Industrial; Lin Hongyuan, Yihe Medical, and Tonghui Medical are concerted parties of Yanghe Industrial[90](index=90&type=chunk) Top Ten Restricted Shareholders | No | Shareholder Name | Restricted Shares Held (shares) | Tradable Date | Newly Tradable Shares (shares) | Restriction Condition | | :--- | :--- | :--- | :--- | :--- | :--- | | 1 | Shanghai Yanghe Industrial Co, Ltd | 47,095,761 | 2025/11/8 | 0 | 36 months | | 2 | Lin Hongyuan | 2,825,745 | 2025/11/8 | 0 | 36 months | | 3 | Hu Zhengguo | 60,000 | Determined by the 2023 Restricted Stock Incentive Plan | - | Equity incentive restricted shares | [Section 7 Bond-Related Matters](index=39&type=section&id=%E7%AC%AC%E4%B8%83%E8%8A%82%20%E5%80%BA%E5%88%B8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) The company has no outstanding corporate bonds, enterprise bonds, non-financial enterprise debt financing instruments, or convertible bonds - The company has no corporate bonds (including enterprise bonds) or non-financial enterprise debt financing instruments[94](index=94&type=chunk) - The company has no convertible corporate bonds[94](index=94&type=chunk) [Section 8 Financial Report](index=40&type=section&id=%E7%AC%AC%E5%85%AB%E8%8A%82%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E5%91%8A) This section presents the unaudited financial statements and detailed notes, reflecting the company's financial position and performance based on a going concern basis - This financial report is **unaudited**[96](index=96&type=chunk) - The financial statements are prepared on a going concern basis, with no material uncertainties identified that would cast significant doubt on the company's ability to continue for the next 12 months[129](index=129&type=chunk)[130](index=130&type=chunk) - The company's principal activities are the R&D, production, and sale of pharmaceuticals such as eye drops and injections, as well as medical services[128](index=128&type=chunk) - The financial statements comply with Corporate Accounting Standards, providing a true and fair view of the company's financial position, operating results, and cash flows[132](index=132&type=chunk) [I. Audit Report](index=40&type=section&id=%E4%B8%80%E3%80%81%E5%AE%A1%E8%AE%A1%E6%8A%A5%E5%91%8A) This semi-annual report is unaudited[96](index=96&type=chunk) - This semi-annual report is **unaudited**[96](index=96&type=chunk) [II. Financial Statements](index=40&type=section&id=%E4%BA%8C%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the consolidated and parent company financial statements for the period ended June 30, 2025 Key Consolidated Balance Sheet Data (June 30, 2025) | Item | Closing Balance (yuan) | Opening Balance (yuan) | | :--- | :--- | :--- | | Cash and Cash Equivalents | 88,639,588.45 | 82,787,450.93 | | Trading Financial Assets | 100,417,450.84 | 106,860,727.24 | | Inventories | 110,933,958.38 | 76,660,507.89 | | Total Current Assets | 391,723,580.79 | 366,665,116.02 | | Fixed Assets | 457,383,108.78 | 477,127,893.05 | | Total Assets | 2,103,716,207.09 | 2,106,253,035.91 | | Short-term Borrowings | 120,178,802.78 | 105,294,386.11 | | Total Liabilities | 490,640,732.68 | 516,587,993.08 | | Total Equity Attributable to Parent | 1,613,043,799.81 | 1,589,629,316.96 | | Total Equity | 1,613,075,474.41 | 1,589,665,042.83 | Key Consolidated Income Statement Data (Jan-Jun 2025) | Item | H1 2025 (yuan) | H1 2024 (yuan) | | :--- | :--- | :--- | | Total Operating Revenue | 236,090,840.96 | 236,852,225.90 | | Total Operating Costs | 209,229,737.85 | 258,887,035.42 | | Total Profit | 21,428,042.32 | -20,663,325.25 | | Net Profit | 21,858,804.22 | -24,819,540.86 | | Net Profit Attributable to Parent Shareholders | 21,862,855.49 | -24,716,934.81 | | Basic Earnings Per Share (yuan/share) | 0.06 | -0.07 | | Diluted Earnings Per Share (yuan/share) | 0.06 | -0.07 | Key Consolidated Cash Flow Statement Data (Jan-Jun 2025) | Item | H1 2025 (yuan) | H1 2024 (yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 51,450,766.00 | -10,125,489.07 | | Net Cash Flow from Investing Activities | -51,035,320.55 | -257,348,885.56 | | Net Cash Flow from Financing Activities | 5,436,692.07 | 62,974,670.10 | | Net Increase in Cash and Cash Equivalents | 5,852,137.52 | -204,499,704.53 | | Closing Balance of Cash and Cash Equivalents | 88,639,588.45 | 151,167,004.23 | [III. Company Basic Information](index=60&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) Zhejiang Shapuaisi Pharmaceutical Co, Ltd is a publicly traded company specializing in pharmaceutical R&D, manufacturing, sales, and medical services - Zhejiang Shapuaisi Pharmaceutical Co, Ltd was established as a joint-stock company on December 15, 2008, through the overall conversion of its predecessor[128](index=128&type=chunk) - The company's shares were listed on the Shanghai Stock Exchange on July 2, 2014[128](index=128&type=chunk) - The company has a registered capital of **375,925,005.00 yuan** and a total of 375,925,005 shares[128](index=128&type=chunk) - The company operates in the pharmaceutical industry, with principal activities in the R&D, production, and sale of pharmaceuticals and the provision of medical services[128](index=128&type=chunk) [IV. Basis of Preparation for Financial Statements](index=60&type=section&id=%E5%9B%9B%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E7%9A%84%E7%BC%96%E5%88%B6%E5%9F%BA%E7%A1%80) The financial statements are prepared on a going concern basis in accordance with Corporate Accounting Standards, fairly presenting the company's financial position - These financial statements have been prepared on a **going concern basis**[129](index=129&type=chunk) - There are no events or conditions that cast significant doubt on the company's ability to continue as a going concern for the next 12 months from the reporting date[130](index=130&type=chunk) - The financial statements prepared by the company comply with the requirements of Corporate Accounting Standards and provide a true and complete view of the company's financial position, operating results, and cash flows[132](index=132&type=chunk) [V. Significant Accounting Policies and Estimates](index=60&type=section&id=%E4%BA%94%E3%80%81%E9%87%8D%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%94%BF%E7%AD%96%E5%8F%8A%E4%BC%9A%E8%AE%A1%E4%BC%B0%E8%AE%A1) This section outlines the company's specific accounting policies for key areas such as financial instruments, inventory, fixed assets, and revenue recognition - The company has formulated specific accounting policies and estimates for transactions and events such as financial instrument impairment, inventory, fixed asset depreciation, right-of-use asset depreciation, intangible asset amortization, goodwill impairment, and revenue recognition[131](index=131&type=chunk) - The company's accounting year is from January 1 to December 31[133](index=133&type=chunk) - The company uses a **12-month period** to classify assets and liabilities as current or non-current, reflecting its short operating cycle[134](index=134&type=chunk) - The company defines individual other receivables exceeding **0.5% of total assets** as significant and construction in progress projects exceeding **50 million yuan** as major[136](index=136&type=chunk)[137](index=137&type=chunk) - Financial assets are classified at initial recognition into three categories: measured at amortized cost, measured at fair value through other comprehensive income, or measured at fair value through profit or loss[141](index=141&type=chunk) - The company recognizes loss allowances for expected credit losses on financial assets measured at amortized cost, debt instruments at FVTOCI, contract assets, and lease receivables[148](index=148&type=chunk) - Revenue from product sales and medical services is recognized at a point in time when control is transferred to the customer, either upon product delivery or service provision[196](index=196&type=chunk) [VI. Taxes](index=76&type=section&id=%E5%85%AD%E3%80%81%E7%A8%8E%E9%A1%B9) This section details the company's main taxes and applicable rates, including preferential tax treatments for high-tech and advanced manufacturing enterprises Main Taxes and Tax Rates | Tax Type | Tax Basis | Tax Rate | | :--- | :--- | :--- | | Value-Added Tax (VAT) | Sales revenue and taxable service income, net of deductible input tax | 13%, 9%, 6%, 5%, 3% | | Consumption Tax | Taxable sales amount (volume) | 10% | | Urban Maintenance and Construction Tax | Actual turnover tax paid | 7%, 5% | | Corporate Income Tax (CIT) | Taxable income | 15%, 20%, 25% | | Property Tax | 1.2% of the residual value (original value less 30%) or 12% of rental income | 1.2%, 12% | | Education Surcharge | Actual turnover tax paid | 3% | | Local Education Surcharge | Actual turnover tax paid | 2% | - The parent company was re-certified as a **High-Tech Enterprise** in December 2023, qualifying for a reduced CIT rate of **15%** for three years, including 2024[210](index=210&type=chunk) - As an advanced manufacturing enterprise, the company is eligible for a **5% additional input VAT deduction** from January 1, 2023, to December 31, 2027[210](index=210&type=chunk) - Certain subsidiaries qualify as small and micro-enterprises, enjoying a preferential CIT policy where annual taxable income up to 3 million yuan is taxed at **20%** on 25% of the income[210](index=210&type=chunk)[211](index=211&type=chunk) [VII. Notes to Consolidated Financial Statement Items](index=77&type=section&id=%E4%B8%83%E3%80%81%E5%90%88%E5%B9%B6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E9%A1%B9%E7%9B%AE%E6%B3%A8%E9%87%8A) This section provides a detailed breakdown and explanation of key items in the consolidated financial statements as of June 30, 2025 Cash and Cash Equivalents (Unit: yuan) | Item | Closing Balance | Opening Balance | | :--- | :--- | :--- | | Cash on Hand | 1,017,462.27 | 610,362.38 | | Bank Deposits | 87,622,126.18 | 81,958,651.80 | | Other Monetary Funds | - | 218,436.75 | | Total | 88,639,588.45 | 82,787,450.93 | Trading Financial Assets (Unit: yuan) | Item | Closing Balance | Opening Balance | | :--- | :--- | :--- | | Financial assets at FVTPL | 100,417,450.84 | 106,860,727.24 | | Of which: Stocks | 96,916,339.13 | 102,891,597.99 | | Wealth Management Products | 3,501,111.71 | 3,501,111.71 | | Performance Commitment Compensation | - | 468,017.54 | | Total | 100,417,450.84 | 106,860,727.24 | Accounts Receivable by Bad Debt Provision Method (Unit: yuan) | Category | Book Balance (Closing) | Bad Debt Provision (Closing) | Book Value (Closing) | | :--- | :--- | :--- | :--- | | Provision by portfolio | 34,855,260.65 | 1,764,438.26 | 33,090,822.39 | | Total | 34,855,260.65 | 1,764,438.26 | 33,090,822.39 | Inventory by Category (Unit: yuan) | Item | Book Balance (Closing) | Provision for Decline in Value (Closing) | Book Value (Closing) | | :--- | :--- | :--- | :--- | | Raw Materials | 37,324,110.09 | 4,320,411.17 | 33,003,698.92 | | Work in Progress | 49,651,998.85 | - | 49,651,998.85 | | Finished Goods | 28,339,172.50 | 340,108.78 | 27,999,063.72 | | Revolving Materials | 279,196.89 | - | 279,196.89 | | Total | 115,594,478.33 | 4,660,519.95 | 110,933,958.38 | Fixed Assets (Unit: yuan) | Item | Buildings and Structures | General Equipment | Machinery and Equipment | Transportation Equipment | Total | | :--- | :--- | :--- | :--- | :--- | :--- | | I. Gross Value: Closing Balance | 373,994,185.06 | 11,850,610.41 | 571,097,510.88 | 16,589,780.40 | 973,532,086.75 | | II. Accumulated Depreciation: Closing Balance | 148,226,446.05 | 9,053,613.39 | 325,161,417.48 | 13,180,101.05 | 495,621,577.97 | | III. Impairment Provision: Closing Balance | - | - | 20,527,400.00 | - | 20,527,400.00 | | IV. Net Book Value: Closing Balance | 225,767,739.01 | 2,796,997.02 | 225,408,693.40 | 3,409,679.35 | 457,383,108.78 | Construction in Progress (Unit: yuan) | Project | Closing Book Balance | Closing Book Value | | :--- | :--- | :--- | | Women's and Children's Hospital New Building Project | 333,626,522.69 | 333,626,522.69 | | Miscellaneous Projects | 2,807,023.15 | 2,807,023.15 | | Total | 336,433,545.84 | 336,433,545.84 | Operating Revenue and Costs (Unit: yuan) | Item | Current Period (Revenue) | Current Period (Cost) | Prior Period (Revenue) | Prior Period (Cost) | | :--- | :--- | :--- | :--- | :--- | | Main Business Revenue | 224,161,904.38 | 90,455,551.02 | 224,449,322.73 | 111,759,676.19 | | Other Business Revenue | 11,928,936.58 | 3,264,361.42 | 12,402,903.17 | 3,217,890.90 | | Total | 236,090,840.96 | 93,719,912.44 | 236,852,225.90 | 114,977,567.09 | Total Profit (Unit: yuan) | Item | H1 2025 | H1 2024 | | :--- | :--- | :--- | | Total Profit | 21,428,042.32 | -20,663,325.25 | [VIII. R&D Expenditures](index=125&type=section&id=%E5%85%AB%E3%80%81%E7%A0%94%E5%8F%91%E6%94%AF%E5%87%BA) The company's R&D expenditure totaled 22.92 million yuan, with 11.15 million yuan capitalized for key eye drop development projects R&D Expenditure by Nature (Unit: yuan) | Item | Current Period | Prior Period | | :--- | :--- | :--- | | Employee Compensation | 3,802,081.82 | 4,536,252.84 | | Materials and Power | 2,506,597.93 | 4,875,319.54 | | Depreciation and Amortization | 1,222,164.07 | 1,596,690.22 | | Commissioned External R&D | 2,742,457.55 | 21,914,000.00 | | Other | 1,495,776.75 | 2,655,502.38 | | Development Expenditures | 11,148,021.81 | 17,509,254.99 | | Total | 22,917,099.93 | 53,087,019.97 | | Of which: Expensed R&D | 11,769,078.12 | 35,577,764.98 | | Capitalized R&D | 11,148,021.81 | 17,509,254.99 | Capitalized R&D Project Development Expenditures (Unit: yuan) | Project | Opening Balance | Current Period Increase (Internal Development) | Closing Balance | | :--- | :--- | :--- | :--- | | Atropine Sulfate Eye Drops R&D | 30,559,414.41 | 712,809.38 | 31,272,223.79 | | Pilocarpine Hydrochloride Eye Drops R&D | 17,263,260.42 | 3,864,095.45 | 21,127,355.87 | | Lifitegrast Eye Drops R&D | 8,510,846.38 | 673,648.47 | 9,184,494.85 | | Azithromycin Eye Drops R&D | 5,774,088.35 | 5,884,683.54 | 11,658,771.89 | | Cetirizine Hydrochloride Eye Drops R&D | 3,312,000.00 | 12,784.97 | 3,324,784.97 | | Total | 65,419,609.56 | 11,148,021.81 | 76,567,631.37 | Significant Capitalized R&D Projects | Project | R&D Progress | Estimated Completion | Expected Economic Benefit | Capitalization Start Date | Basis for Capitalization | | :--- | :--- | :--- | :--- | :--- | :--- | | Atropine Sulfate Eye Drops R&D | Phase III trial enrollment completed | 2029 | Sales from drug launch | July 2023 | Entered Phase III clinical trial | | Pilocarpine Hydrochloride Eye Drops R&D | Enrollment completed | 2027 | Sales from drug launch | October 2023 | Obtained clinical trial approval | | Lifitegrast Eye Drops R&D | Obtained clinical trial approval notice | 2029 | Sales from drug launch | December 2024 | Obtained clinical trial approval | | Azithromycin Eye Drops R&D | First patient enrolled | 2028 | Sales from drug launch | October 2024 | Obtained clinical trial approval | | Cetirizine Hydrochloride Eye Drops R&D | Obtained clinical trial approval notice | 2029 | Sales from drug launch | December 2024 | Obtained clinical trial approval | [IX. Changes in the Scope of Consolidation](index=128&type=section&id=%E4%B9%9D%E3%80%81%E5%90%88%E5%B9%B6%E8%8C%83%E5%9B%B4%E7%9A%84%E5%8F%98%E6%9B%B4) The company disposed of one subsidiary and established another, resulting in a change to the consolidation scope during the reporting period Disposal of a Subsidiary (Unit: yuan) | Subsidiary Name | Date of Losing Control | Disposal Consideration | Disposal Percentage (%) | Disposal Method | Basis for Losing Control | Difference between Consideration and Net Asset Share | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Zhejiang Shapuaisi Pharmacy Chain Co, Ltd | April 2025 | 1,342,867.61 | 100 | Sale | Completion of business handover | -1,693,019.90 | Additions to Consolidation Scope | Company Name | Method of Acquisition | Date of Acquisition | Capital Contribution (yuan) | Shareholding Ratio (%) | | :--- | :--- | :--- | :--- | :--- | | Pinghu Shapuaisi Limin Pharmacy Co, Ltd | Establishment | March 2025 | 1,100,000.00 | 100.00 | [X. Interests in Other Entities](index=129&type=section&id=%E5%8D%81%E3%80%81%E5%9C%A8%E5%85%B6%E4%BB%96%E4%B8%BB%E4%BD%93%E4%B8%AD%E7%9A%84%E6%9D%83%E7%9B%8A) This section details the company's ownership in its subsidiaries and significant influence over its associate companies, which are accounted for using the equity method Composition of the Corporate Group | Subsidiary Name | Main Operating Location | Registered Location | Business Nature | Direct Holding (%) | Indirect Holding (%) | Acquisition Method | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Shapuaisi Sales Co | Pinghu | Pinghu | Pharmaceutical Sales | 100 | - | Establishment | | Pinghu Shapuaisi Limin Pharmacy | Pinghu | Pinghu | Pharmaceutical Sales | 100 | - | Establishment | | Shapuaisi Trading Co | Pinghu | Pinghu | Pharmaceutical Sales | - | 100 | Establishment | | Women's and Children's Hospital Co | Taizhou | Taizhou | Health Industry | 100 | - | Business combination not under common control | | Maternity Hospital Co | Taizhou | Taizhou | Medical Services | - | 100 | Business combination not under common control | | Shenzhen Jiusongtang Co | Shenzhen | Shenzhen | Investment | 85.71 | - | Establishment | | Zhejiang Shapu Health Management | Pinghu | Pinghu | Consulting Services | 100 | - | Establishment | | Taizhou Kangbeijia Maternal Care | Taizhou | Taizhou | Sales | - | 100 | Establishment | | Taizhou Kangbeirui Maternal Care | Taizhou | Taizhou | Consulting Services | - | 100 | Establishment | | Taizhou Kangsen Network Tech | Taizhou | Taizhou | Technical Services | - | 100 | Establishment | | Taizhou Yiyaotong Medical Tech | Taizhou | Taizhou | Technical Services | - | 100 | Establishment | | Taizhou Herui Pharmacy | Taizhou | Taizhou | Pharmaceutical Sales | - | 100 | Establishment | | Qingdao Shijian Eye Hospital | Qingdao | Qingdao | Medical Services | 100 | - | Business combination not under common control | | Qingdao Xinchen Medical Consulting | Qingdao | Qingdao | Consulting Services | - | 100 | Business combination not under common control | | Qingdao Kangshi Health Management | Qingdao | Qingdao | Consulting Services | - | 100 | Establishment | | Qingdao Shijian Hemodialysis | Qingdao | Qingdao | Medical Services | - | 100 | Establishment | | Shanghai Xiongqi Biotech | Shanghai | Shanghai | Technical Services | 100 | - | Establishment | Key Financial Information of Significant Associates (June 30, 2025) | Item | Nanjing Kemer Biomedical Co, Ltd (yuan) | Shanghai Xinhong Pharmaceutical Co, Ltd (yuan) | | :--- | :--- | :--- | | Total Assets | 513,420,717.01 | 428,494,029.57 | | Total Liabilities | 250,188,928.92 | 108,984.55 | | Equity Attributable to Parent | 263,231,788.09 | 428,385,045.02 | | Operating Revenue | 82,389,152.59 | 0 | | Net Profit | 10,402,475.85 | -13,561,981.91 | | Total Comprehensive Income | 10,402,475.85 | -13,561,981.91 | - Shapuaisi holds a **17.8% stake** in Nanjing Kemer Biomedical Co, Ltd and has appointed one director, thus exerting significant influence and using the equity method for accounting[383](index=383&type=chunk) Summarized Financial Information of Insignificant Associates (Unit: yuan) | Item | Closing Balance / Current Period Amount | | :--- | :--- | | Associates: Total book value of investments | 46,493,365.99 | | --Net profit | 170,928.66 | | --Total comprehensive income | 170,928.66 | [XI. Government Grants](index=134&type=section&id=%E5%8D%81%E4%B8%80%E3%80%81%E6%94%BF%E5%BA%9C%E8%A1%A5%E5%8A%A9) The company recognized a total of 4.95 million yuan in government grants in the current period's profit and loss Liabilities Related to Government Grants (Unit: yuan) | Financial Statement Item | Opening Balance | New Grants | Recognized in Non-operating Income | Transferred to Other Income | Other Changes | Closing Balance | Asset/Income Related | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Deferred Income | 2,224,599.21 | - | - | 124,039.98 | - | 2,100,559.23 | Asset-related | | Total | 2,224,599.21 | - | - | 124,039.98 | - | 2,100,559.23 | / | Government Grants Recognized in Current Profit or Loss (Unit: yuan) | Type | Current Period Amount | Prior Period Amount | | :--- | :--- | :--- | | Income-related | 4,828,915.45 | 1,190,246.00 | | Asset-related | 124,039.98 | 124,039.98 | | Total | 4,952,955.43 | 1,314,285.98 | [XII. Risks Related to Financial Instruments](index=135&type=section&id=%E5%8D%81%E4%BA%8C%E3%80%81%E4%B8%8E%E9%87%91%E8%9E%8D%E5%B7%A5%E5%85%B7%E7%9B%B8%E5%85%B3%E7%9A%84%E9%A3%8E%E9%99%A9) The company actively manages credit, liquidity, and market risks to balance risk and return and maximize shareholder value - The company's risk management objective is to balance risk and return, minimize the negative impact of risks on operating performance, and maximize the interests of shareholders[393](index=393&type=chunk) - The company faces various financial instrument-related risks in its daily activities, primarily including **credit risk, liquidity risk, and market risk**[393](index=393&type=chunk) - The company's credit risk mainly arises from cash and cash equivalents and receivables, which is managed by depositing funds in highly-rated financial institutions and conducting credit assessments on customers[396](index=396&type=chunk) - As of June 30, 2025, **62.20% of the company's accounts receivable** were from the top five customers, indicating a certain concentration of credit risk[396](index=396&type=chunk) - To control liquidity risk, the company utilizes various financing methods such as note settlements and bank loans, and optimizes its financing structure by combining long-term and short-term financing[397](index=397&type=chunk) - Market risk primarily includes interest rate risk and foreign exchange risk, managed by adjusting the mix of fixed and floating-rate financial instruments[400](index=400&type=chunk) - As of June 30, 2025, the company had **93.1 million yuan** in floating-rate bank borrowings; foreign exchange risk is not significant as operations are primarily denominated in RMB[400](index=400&type=chunk) [XIII. Fair Value Disclosures](index=138&type=section&id=%E5%8D%81%E4%B8%89%E3%80%81%E5%85%AC%E5%85%81%E4%BB%B7%E5%80%BC%E7%9A%84%E6%8A%AB%E9%9C%B2) The company's assets measured at fair value totaled 141 million yuan, primarily comprising trading financial assets and receivables financing Assets and Liabilities Measured at Fair Value at Period End (Unit: yuan) | Item | Level 1 Fair Value | Level 2 Fair Value | Level 3 Fair Value | Total | | :--- | :--- | :--- | :--- | :--- | | I. Continuous Fair Value Measurement | - | - | - | - | | (I) Trading Financial Assets | 100,417,450.84 | 19,000,000.00 | - | 119,417,450.84 | | (4) Wealth Management Products | 3,501,111.71 | - | - | 3,501,111.71 | | (5) Stock Investments | 96,916,339.13 | - | - | 96,916,339.13 | | (6) Equity Investments | - | 19,000,000.00 | - | 19,000,000.00 | | (VI) Receivables Financing | - | - | 21,661,473.37 | 21,661,473.37 | | Total Assets at Continuous Fair Value | 100,417,450.84 | 19,000,000.00 | 21,661,473.37 | 141,078,924.21 | - **Level 1** fair value for trading financial assets (stocks, bank wealth products) is determined by quoted prices in active markets and observable net asset values[405](index=405&type=chunk) - **Level 2** fair value for other non-current financial assets is determined by referencing recent investment prices or equity transaction values[406](index=406&type=chunk) - **Level 3** fair value for receivables financing (bank acceptance bills) is determined by their face value, given their low credit risk and short remaining terms[407](index=407&type=chunk) [XIV. Related Parties and Transactions](index=140&type=section&id=%E5%8D%81%E5%9B%9B%E3%80%81%E5%85%B3%E8%81%94%E6%96%B9%E5%8F%8A%E5%85%B3%E8%81%94%E4%BA%A4%E6%98%93) This section identifies the company's related parties and discloses transactions, with key management personnel compensation totaling 1.44 million yuan - Shanghai Yanghe Industrial Co, Ltd is the company's parent, with a registered capital of 250 million yuan and holding a **32.44%** equity and voting rights stake[409](index=409&type=chunk) - The ultimate controllers of the company are the brothers **Lin Hongli and Lin Hongyuan**[409](index=409&type=chunk) - The company's significant associates include Nanjing Kemer Biomedical Co, Ltd and Hubei Lingsheng Pharmaceutical Co, Ltd[410](index=410&type=chunk) Related-Party Transactions for Goods/Services (Unit: yuan) | Related Party | Transaction Content | Current Period Amount | Prior Period Amount | | :--- | :--- | :--- | :--- | | Pinghu Jingxing Packaging Materials Co, Ltd | Goods | 917,066.64 | 646,999.52 | | Nanjing Kemer Biomedical Co, Ltd | Technical Services | 1,200,000.00 | 7,100,000.00 | Key Management Personnel Compensation (Unit: ten thousand yuan) | Item | Current Period Amount | Prior Period Amount | | :--- | :--- | :--- | | Key Management Personnel Compensation | 143.68 | 190.78 | Amounts Due from Related Parties (Unit: yuan) | Item | Related Party | Closing Book Balance | Opening Book Balance | | :--- | :--- | :--- | :--- | | Prepayments | Nanjing Kemer Biomedical Co, Ltd | 1,550,000.00 | 1,750,000.00 | | Prepayments | Hubei Lingsheng Pharmaceutical Co, Ltd | 675,000.00 | 865,486.73 | - The closing balance of accounts payable to Pinghu Jingxing Packaging Materials Co, Ltd was **0.00 yuan**, compared to an opening balance of 198,095.18 yuan[419](index=419&type=chunk) [XV. Share-Based Payments](index=143&type=section&id=%E5%8D%81%E4%BA%94%E3%80%81%E8%82%A1%E4%BB%BD%E6%94%AF%E4%BB%98) The company recognized 1.52 million yuan in share-based payment expenses for the period, with a cumulative amount of 4.93 million yuan in capital reserve - The fair value of equity instruments on the grant date is determined by the difference between the grant price and the closing stock price on that day[422](index=422&type=chunk) - The number of vested equity instruments is determined based on the latest data on the number of eligible employees[422](index=422&type=chunk) - The cumulative amount of equity-settled share-based payments recognized in capital reserve is **4,927,681.39 yuan**[422](index=422&type=chunk) Share-Based Payment Expenses for the Current Period (Unit: yuan) | Grantee Category | Equity-Settled Share-Based Payment Expense | | :--- | :--- | | Management Personnel | 991,109.28 | | R&D Personnel | 113,307.72 | | Sales Personnel | 235,280.14 | | Production Personnel | 175,960.22 | | Total | 1,515,657.36 | [XVI. Commitments and Contingencies](index=143&type=section&id=%E5%8D%81%E5%85%AD%E3%80%81%E6%89%BF%E8%AF%BA%E5%8F%8A%E6%88%96%E6%9C%89%E4%BA%8B%E9%A1%B9) The company has no significant commitments or material contingencies to disclose for the reporting period - The company has **no significant commitments**[423](index=423&type=chunk) - The company has **no material contingencies** to disclose[424](index=424&type=chunk) [XVII. Subsequent Events](index=144&type=section&id=%E5%8D%81%E4%B8%83%E3%80%81%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8%E6%97%A5%E5%90%8E%E4%BA%8B%E9%A1%B9) No significant subsequent events, including non-adjusting events or profit distributions, occurred after the balance sheet date - The company has **no significant non-adjusting events**[424](index=424&type=chunk) - The company has **no profit distribution plans**[424](index=424&type=chunk) - The company has **no sales returns** to report[424](index=424&type=chunk) - The company has **no other subsequent events** to disclose[424](index=424&type=chunk) [XVIII. Other Significant Matters](index=145&type=section&id=%E5%8D%81%E5%85%AB%E3%80%81%E5%85%B6%E4%BB%96%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) The company continues to advance the consistency evaluation for its core product and reports financial information based on two main operating segments - The company continues to fully advance the consistency evaluation work for Bendazac Lysine Eye Drops (Shapuaisi)[430](index=430&type=chunk) - The post-marketing clinical study for Bendazac Lysine Eye Drops (Shapuaisi) has been completed and submitted to the NMPA as required[430](index=430&type=chunk) - The company determines its reportable segments based on its internal organizational structure, management requirements, and internal reporting systems, using industry segments as the basis[425](index=425&type=chunk) Financial Information by Reportable Segment (Unit: yuan) | Item | Goods Sales | Medical Services | Inter-segment Elimination | Total | | :--- | :--- | :--- | :--- | :--- | | Main Business Revenue | 155,441,670.41 | 68,720,233.97 | - | 224,161,904.38 | | Main Business Costs | 38,829,208.32 | 51,626,342.70 | - | 90,455,551.02 | | Total Assets | 1,447,590,616.15 | 656,125,590.94 | - | 2,103,716,207.09 | | Total Liabilities | 356,741,412.29 | 133,899,320.39 | - | 490,640,732.68 | [XIX. Notes to Parent Company Financial Statement Items](index=146&type=section&id=%E5%8D%81%E4%B9%9D%E3%80%81%E6%AF%8D%E5%85%AC%E5%8F%B8%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E4%B8%BB%E8%A6%81%E9%A1%B9%E7%9B%AE%E6%B3%A8%E9%87%8A) This section provides detailed notes on key items in the parent company's financial statements, including receivables, long-term investments, and revenue Parent Company Accounts Receivable by Bad Debt Provision Method (Unit: yuan) | Category | Book Balance (Closing) | Bad Debt Provision (Closing) | Book Value (Closing) | | :--- | :--- | :--- | :--- | | Provision by portfolio | 11,214,351.05 | 220,221.82 | 10,994,129.23 | | Total | 11,214,351.05 | 220,221.82 | 10,994,129.23 | Parent Company Other Receivables by Nature (Unit: yuan) | Nature | Closing Book Balance | Opening Book Balance | | :--- | :--- | :--- | | Deposits and Guarantees | 1,985,216.00 | 2,448,918.29 | | Intercompany Balances with Subsidiaries | 116,125,453.84 | 78,342,274.86 | | Temporary Payments Receivable | 810,543.97 | 7,016,569.42 | | Other | 5,049,870.31 | 587,054.16 | | Total | 123,971,084.12 | 88,394,816.73 | Parent Company Long-Term Equity Investments (Unit: yuan) | Item | Closing Book Value | Opening Book Value | | :--- | :--- | :--- | | Investments in Subsidiaries | 969,282,800.00 | 968,182,800.00 | | Investments in Associates and Joint Ventures | 258,061,924.06 | 260,916,738.39 | | Total | 1,227,344,724.06 | 1,229,099,538.39 | Parent Company Operating Revenue and Costs (Unit: yuan) | Item | Current Period (Revenue) | Current Period (Cost) | Prior Period (Revenue) | Prior Period (Cost) | | :--- | :--- | :--- | :--- | :--- | | Main Business | 151,371,912.06 | 42,071,176.64 | 134,575,502.28 | 58,402,778.33 | | Other Business | 7,996,381.08 | 978,822.26 | 3,454,728.38 | 938,554.86 | | Total | 159,368,293.14 | 43,049,998.90 | 138,030,230.66 | 59,341,333.19 | Parent Company Investment Income (Unit: yuan) | Item | Current Period Amount | Prior Period Amount | | :--- | :--- | :--- | | Income from long-term equity investments under the equity method | -2,854,814.33 | 3,710,791.51 | | Investment income from disposal of trading financial assets | 2,719,076.13 | - | | Income from wealth management products | - | 92,000.00 | | Interest on note discounting | -500,962.13 | -441,025.64 | | Investment income from disposal of other non-current financial assets | 225,000.00 | - | | Total | -411,700.33 | 3,361,765.87 | [XX. Supplementary Information](index=157&type=section&id=%E4%BA%8C%E5%8D%81%E3%80%81%E8%A1%A5%E5%85%85%E8%B5%84%E6%96%99) This section provides a detailed breakdown of non-recurring gains and losses and key return metrics for the reporting period Detailed Schedule of Non-recurring Gains and Losses for H1 2025 (Unit: yuan) | Item | Amount | | :--- | :--- | | Gains/losses from disposal of non-current assets, including write-offs of asset impairment provisions | 788,664.70 | | Government grants recognized in current profit or loss, excluding those closely related to normal business operations | 4,828,915.45 | | Fair value changes and disposal gains/losses from financial assets and liabilities held by non-financial enterprises, excluding effective hedging activities | -5,966,552.53 | | Other non-operating income and expenses | 277,911.25 | | Less: Income tax impact | -249,632.71 | | Total | 178,571.58 | Return on Equity and Earnings Per Share for H1 2025 | Profit for the Period | Weighted Average Return on Equity (%) | Earnings Per Share (yuan) | | :--- | :--- | :--- | | Net profit attributable to common shareholders | 1.37 | 0.06 | | Net profit attributable to common shareholders after deducting non-recurring items | 1.35 | 0.06 |

(2025 年 8 月) 第一章 总则 本制度所称"控股股东"是指具备下列条件之一的股东：持有的股份 占公司股本总额超过50%的股东；或者持有股份的比例虽然未超过50%， 但依其持有的股份所享有的表决权已足以对股东会的决议产生重大 影响的股东；有关法律法规和中国证券监督管理委员会（以下简称"中 国证监会"）及上海证券交易所认定的其他情形。 本制度所称"实际控制人"是指：通过投资关系、协议或者其他安排， 能够实际支配公司行为的自然人、法人或者其他组织。 第一条 为进一步维护浙江莎普爱思药业股份有限公司(以下简称"公司") 全体股东利益，建立防范控股股东及关联方占用公司及子公司资金的 长效机制，杜绝控股股东及关联方资金占用行为的发生，根据《中华 人民共和国公司法》、《中华人民共和国证券法》、《上海证券交易所股 票上市规则》等法律、法规及规范性文件以及《浙江莎普爱思药业股 份有限公司章程》等有关规定，制定本制度。 第二条 本制度适用于公司控股股东、实际控制人及其他关联方与公司间的资 金管理。公司控股股东、实际控制人及其他关联方与纳入公司合并会 计报表范围的子公司之间的资金往来适用本制度。 本制度所称"实际控制人"是 ...

浙江莎普爱思药业股份有限公司 募集资金管理办法 (2025年8月) 为加强、规范浙江莎普爱思药业股份有限公司(以下简称"公司")募集资金 的管理,提高募集资金使用效率和效益,根据《中华人民共和国公司法》、《中华 人民共和国证券法》、《上海证券交易所股票上市规则》(以下简称"《上市规 则》")、《上海证券交易所上市公司自律监管指引第1号——规范运作》等法律 法规和规范性文件,以及《浙江莎普爱思药业股份有限公司章程》("以下简称 "《公司章程》")的规定,结合公司实际情况,特制定本办法。 第一条 本办法所称募集资金，是指公司通过发行股票或者其他具有股权性 质的证券，向投资者募集并用于特定用途的资金，但不包括公司为实施股权激 励计划募集的资金。超募资金，是指实际募集资金净额超过计划募集资金金额 的部分。 第二条 公司董事会建立募集资金存储、使用和管理的内部控制制度，对募 集资金存储、使用、变更、监督和责任追究以及募集资金使用的申请、分级审批 权限、决策程序、风险控制措施及信息披露程序等内容进行明确规定。 第三条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业 政策和相关法律法规，践行可持续发展理念，履行 ...

浙江莎普爱思药业股份有限公司 累积投票制实施细则 浙江莎普爱思药业股份有限公司 累积投票制实施细则 ((2025年8月) 第一章 总 则 浙江莎普爱思药业股份有限公司 累积投票制实施细则 第三章 董事候选人的投票 第十条 采用累积投票制时，股东会对董事候选人进行表决前，股东会主持人应明确 告知与会股东对候选董事实行累积投票方式，董事会必须置备适合实行累积 投票方式的选票。董事会秘书应对累积投票方式、选票填写方法做出说明和 解释。 2 第五条 股东会选举产生的董事人数及结构应符合《公司章程》的规定。按照拟选任 的人数，根据符合提名条件的股东、董事会的初步提名，由董事会提名委员 会提出董事候选人的建议名单，经董事会决议通过后，由董事会向股东会 提出董事候选人并提交股东会选举。 第六条 提名人在提名前应当征得被提名人的同意。董事候选人应在股东会召开前作 出书面承诺，同意接受提名并公开本人的详细资料，承诺公开披露的董事 候选人的资料真实、完整，并保证当选后切实履行董事职责。独立董事候选 人还应当就其本人与公司之间不存在任何影响其独立客观判断的关系发表声 明。 第七条 被提名人应向公司董事会提交个人详细资料，包括但不限 ...

浙江莎普爱思药业股份有限公司 董事会议事规则 浙江莎普爱思药业股份有限公司 董事会议事规则 (2025 年 8 月) 第一章 总则 第一条 宗旨 为了进一步规范浙江莎普爱思药业股份有限公司(以下简称"公司")董事会的 议事方式和决策程序，促使董事和董事会有效地履行其职责，提高董事会规范 运作和科学决策水平，根据《公司法》、《证券法》、《上市公司治理准则》、《上 海证券交易所股票上市规则》(以下简称"《上市规则》")和《公司章程》等有 关规定，制订本规则。 第二章 董事会的组成和职权 （六）拟订公司重大收购、收购本公司股票或者合并、分立、解散及变更公 司形式的方案； 1 第二条 公司依法设立董事会。 第三条 公司董事会人员组成根据《公司章程》确定。 第四条 董事会行使下列职权： （一）召集股东会，并向股东会报告工作； （二）执行股东会的决议； （三）决定公司的经营计划和投资方案； （四）制订公司的利润分配方案和弥补亏损方案； （五）制订公司增加或减少注册资本、发行债券或其他证券及上市方案； 浙江莎普爱思药业股份有限公司 董事会议事规则 （七）在股东会授权范围内，决定公司对外投资、收购出售资产、资产抵押、 对外担 ...

浙江莎普爱思药业股份有限公司 董事会提名委员会工作细则 浙江莎普爱思药业股份有限公司 董事会提名委员会工作细则 (2025年8月) 第一节 总则 提名委员会对董事会负责，依照《公司章程》、本工作细则的规定和董事会 授权履行职责。提名委员会的提案应当提交董事会审议决定。 第二节 人员组成 1 第一条 为完善浙江莎普爱思药业股份有限公司(以下简称"公司")法人治理结构，增 强董事会选举程序的科学性、民主性，优化董事会的组成人员结构，公司特 设立董事会提名委员会。 第二条 为使提名委员会规范、高效地开展工作，公司董事会根据《中华人民共和国 公司法》(以下简称"《公司法》")、《上市公司治理准则》等有关法律、法 规和规范性文件以及《公司章程》的有关规定，制订本工作细则。 第三条 提名委员会是董事会设立的专门工作机构，主要负责拟定公司董事、高级管 理人员的选择标准和程序，对董事、高级管理人员人选及其任职资格进行遴 选、审核、提议等相关工作。 第四条 提名委员会委员由三名董事组成，其中独立董事应不少于两名并担任召集人。 第五条 提名委员会委员由董事长、二分之一以上独立董事或者全体董事的三分之一 提名，并由董事会选举产生。 ...

浙江莎普爱思药业股份有限公司 关联交易决策制度 (2025 年 10 月) 第一章 总则 第一条 为规范浙江莎普爱思药业股份有限公司（以下简称"公司"）的关联交易 行为，保护公司、股东和债权人的合法权益，保证本公司关联交易决策 行为的公允性，根据《中华人民共和国公司法》、《中华人民共和国证券 法》、《上海证券交易所股票上市规则》及国家证券主管部门和本公司章 程的有关规定，制定本制度。 第二章 关联人和关联交易 第二条 关联交易的定义:关联交易是指公司或公司控股子公司与关联人(定义见 下文第三条)之间发生的转移资源或义务的事项，具体包括: (一) 购买或出售资产； (二) 对外投资(含委托理财、对子公司投资等)； (三) 提供财务资助； (四) 提供担保（含对控股子公司担保等）； (五) 租入或租出资产； (六) 委托或者受托管理资产和业务； (七) 赠与或受赠资产； (八) 债权或债务重组； (九) 签订许可使用协议； (十) 转让或者受让研究与开发项目； (十一) 放弃权利（含放弃优先购买权、优先认缴出资权等）； (十二) 购买原材料、燃料、动力； (十三) 销售产品、商品； (十四) 提供或接受劳务； ( ...

浙江莎普爱思药业股份有限公司 信息披露暂缓与豁免事务管理制度 （2025年8月） 第五条 信息披露义务人拟披露的信息属于国家秘密、商业秘密等情形，按《股票 上市规则》披露或者履行相关义务可能导致其违反国家有关保密的法律法 规或损害上市公司及投资者利益的，可以豁免披露。 第六条 本制度所称的商业秘密，是指国家有关反不正当竞争法律法规及部门规章 规定的，不为公众所知悉、能为权利人带来经济利益、具有实用性并经权 利人采取保密措施的技术信息和经营信息。 第七条 本制度所称的国家秘密，是指国家有关保密法律法规及部门规章规定的， 关系国家安全和利益，依照法定程序确定，在一定时间内只限一定范围的 人员知悉，泄露后可能损害国家在政治、经济、国防、外交等领域的安全 和利益的信息。 第八条 暂缓、豁免披露的信息应当符合下列条件： （一）相关信息尚未泄漏； （二）有关内幕人士已书面承诺保密； （三）公司股票及其衍生品种的交易未发生异常波动。 暂缓、豁免披露的原因已经消除或者期限届满的，公司应当及时公告相关 信息，并披露此前该信息暂缓、豁免披露的事由、公司内部登记审核等情 况。 第四章 责任与处罚 第十一条 公司确立信息披露暂缓、豁 ...